Cepheid to develop rapid tuberculosis test for developing nations

By Elaine Rigoli

Tampa, Fla., May 23 - Cepheid announced a collaboration with the Foundation for Innovative New Diagnostics to develop a new rapid molecular diagnostic test for tuberculosis (TB) that will run on Cepheid's GeneXpert System.

Without easy-to-use diagnostics, too many TB cases go undetected and the disease continues to kill nearly 2 million people a year, officials said.

The new system will allow health care providers to obtain timely, accurate results from virtually any type of raw biological sample, with minimal risk of contamination.

The system is designed to operate in a wide range of environments, including hospitals, public health clinics, physician offices and industrial settings as applicable, the company said in a news release.

The Foundation for Innovative New Diagnostics, located in Geneva, Switzerland, is a non-profit foundation dedicated to the development of simple, accessible diagnostic tools.

Cepheid, based in Sunnyvale, Calif., is a molecular diagnostics company that develops systems for genetic analysis in the clinical, industrial and biothreat markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.